BVXP Bioventix PLC

25.68USD1950.00 GBp · LSE0.00%Mkt Cap: 134.17M USDP/E: 13.54

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertilit…

Key Statistics

Company
Market Cap134.17M USD
Enterprise Value127.25M USD
Revenue (TTM)17.08M USD
Gross Profit15.69M USD
Net Income (TTM)9.99M USD
Revenue/Share3.27 USD
Last Price25.68 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees11
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB00B4QVDF07
Valuation
P/E (Trailing)13.54
P/E (Forward)0.11
PEG—
EV/EBITDA9.58
EV/Revenue7.45
P/S7.85
P/B8.92
EPS (TTM)1.90 USD
EPS (Forward)236.11 USD
52W Range
0.000086% of range29.69
52W High29.69 USD
52W Low0.0000 USD
Profitability
Gross Margin90.86%
Oper. Margin77.28%
EBITDA Margin77.72%
Profit Margin57.83%
ROE65.66%
ROA58.96%
ROIC—
ROCE87.20%
Growth
Revenue Growth6.70%
Earnings Growth4.20%
Cash Flow & Leverage
Operating CF9.26M USD
CapEx (TTM)25.27K USD
FCF Margin51.44%
FCF Yield6.55%
Net Debt-6.92M USD
Net Debt/EBITDA-0.52
Net Debt/FCF-0.79
Balance Sheet
Debt/Equity0.03
Current Ratio8.53
Quick Ratio4.78
Book Value/Sh2.88 USD
Cash/Share1.33 USD
Dividends
Fwd Div Rate0.02 USD
Trail. Div Rate0.02 USD
Div. Yield7.69%
5Y Avg Yield4.32%
Payout Ratio104.43%
Ex-Div DateNov 5, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)51.36 USD
Upside (mean)+100.0%
Target Range51.36 USD – 51.36 USD
# Analysts1
Ownership
Shares Out.5.22M
Float4.15M
Insiders7.70%
Institutions59.00%
Technical
SMA 5023.45 (+9.5%)
SMA 20021.96 (+16.9%)
Beta0.51
S&P 52W Chg12.08%
Avg Vol (30d)17.97K
Avg Vol (10d)27.23K
Technical Indicators
RSI (14)55.1
MACD33.2855
MACD Signal48.4737
MACD Hist.-15.1882
BB Upper27.17 USD
BB Middle26.06 USD
BB Lower24.95 USD
BB Width8.53%
ATR (14)1.604 USD
Vol Ratio (20d)0.18x

About Bioventix (LON: BVXP)

›

Bioventix (LON: BVXP) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 11 employees.

The shares were at 1950.00 GBp on 19 November 2026, down 10.3% over 52 weeks.

At a market capitalisation of 101.88M GBP, it trades at 13.5 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 60% for BVXP. It pays a dividend yielding 7.69% (it pays out 104% of its earnings), against a median of 0.94% among the dividend payers in that peer group.

Bioventix reports return on equity of 65.7%, an operating margin of 77.3% and revenue up 6.7% year over year.

It holds more cash than debt, a net cash position of 5.25M GBP. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 3900.00 GBp is 100.0% above the current price.